Cargando…
Real-world evidence studies into treatment adherence, thresholds for intervention and disparities in treatment in people with type 2 diabetes in the UK
PURPOSE: The University of Surrey-Lilly Real World Evidence (RWE) diabetes cohort has been established to provide insights into the management of type 2 diabetes mellitus (T2DM). There are 3 areas of study due to be conducted to provide insights into T2DM management: exploration of medication adhere...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5168506/ https://www.ncbi.nlm.nih.gov/pubmed/27884846 http://dx.doi.org/10.1136/bmjopen-2016-012801 |
_version_ | 1782483357085466624 |
---|---|
author | McGovern, Andrew Hinton, William Correa, Ana Munro, Neil Whyte, Martin de Lusignan, Simon |
author_facet | McGovern, Andrew Hinton, William Correa, Ana Munro, Neil Whyte, Martin de Lusignan, Simon |
author_sort | McGovern, Andrew |
collection | PubMed |
description | PURPOSE: The University of Surrey-Lilly Real World Evidence (RWE) diabetes cohort has been established to provide insights into the management of type 2 diabetes mellitus (T2DM). There are 3 areas of study due to be conducted to provide insights into T2DM management: exploration of medication adherence, thresholds for changing diabetes therapies, and ethnicity-related or socioeconomic-related disparities in management. This paper describes the identification of a cohort of people with T2DM which will be used for these analyses, through a case finding algorithm, and describes the characteristics of the identified cohort. PARTICIPANTS: A cohort of people with T2DM was identified from the Royal College of General Practitioners Research and Surveillance Centre (RCGP RSC) data set. This data set comprises electronic patient records collected from a nationally distributed sample of 130 primary care practices across England with scope to increase the number of practices to 200. FINDINGS TO DATE: A cohort (N=58 717) of adults with T2DM was identified from the RCGP RSC population (N=1 260 761), a crude prevalence of diabetes of 5.8% in the adult population. High data quality within the practice network and an ontological approach to classification resulted in a high level of data completeness in the T2DM cohort; ethnicity identification (82.1%), smoking status (99.3%), alcohol use (93.3%), glycated haemoglobin (HbA1c; 97.9%), body mass index (98.0%), blood pressure (99.4%), cholesterol (87.4%) and renal function (97.8%). Data completeness compares favourably to other, similarly large, observational cohorts. The cohort comprises a distribution of ages, socioeconomic and ethnic backgrounds, diabetes complications, and comorbidities, enabling the planned analyses. FUTURE PLANS: Regular data uploads from the RCGP RSC practice network will enable this cohort to be followed prospectively. We will investigate medication adherence, explore thresholds and triggers for changing diabetes therapies, and investigate any ethnicity-related or socioeconomic-related disparities in diabetes management. |
format | Online Article Text |
id | pubmed-5168506 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-51685062016-12-22 Real-world evidence studies into treatment adherence, thresholds for intervention and disparities in treatment in people with type 2 diabetes in the UK McGovern, Andrew Hinton, William Correa, Ana Munro, Neil Whyte, Martin de Lusignan, Simon BMJ Open Diabetes and Endocrinology PURPOSE: The University of Surrey-Lilly Real World Evidence (RWE) diabetes cohort has been established to provide insights into the management of type 2 diabetes mellitus (T2DM). There are 3 areas of study due to be conducted to provide insights into T2DM management: exploration of medication adherence, thresholds for changing diabetes therapies, and ethnicity-related or socioeconomic-related disparities in management. This paper describes the identification of a cohort of people with T2DM which will be used for these analyses, through a case finding algorithm, and describes the characteristics of the identified cohort. PARTICIPANTS: A cohort of people with T2DM was identified from the Royal College of General Practitioners Research and Surveillance Centre (RCGP RSC) data set. This data set comprises electronic patient records collected from a nationally distributed sample of 130 primary care practices across England with scope to increase the number of practices to 200. FINDINGS TO DATE: A cohort (N=58 717) of adults with T2DM was identified from the RCGP RSC population (N=1 260 761), a crude prevalence of diabetes of 5.8% in the adult population. High data quality within the practice network and an ontological approach to classification resulted in a high level of data completeness in the T2DM cohort; ethnicity identification (82.1%), smoking status (99.3%), alcohol use (93.3%), glycated haemoglobin (HbA1c; 97.9%), body mass index (98.0%), blood pressure (99.4%), cholesterol (87.4%) and renal function (97.8%). Data completeness compares favourably to other, similarly large, observational cohorts. The cohort comprises a distribution of ages, socioeconomic and ethnic backgrounds, diabetes complications, and comorbidities, enabling the planned analyses. FUTURE PLANS: Regular data uploads from the RCGP RSC practice network will enable this cohort to be followed prospectively. We will investigate medication adherence, explore thresholds and triggers for changing diabetes therapies, and investigate any ethnicity-related or socioeconomic-related disparities in diabetes management. BMJ Publishing Group 2016-11-24 /pmc/articles/PMC5168506/ /pubmed/27884846 http://dx.doi.org/10.1136/bmjopen-2016-012801 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Diabetes and Endocrinology McGovern, Andrew Hinton, William Correa, Ana Munro, Neil Whyte, Martin de Lusignan, Simon Real-world evidence studies into treatment adherence, thresholds for intervention and disparities in treatment in people with type 2 diabetes in the UK |
title | Real-world evidence studies into treatment adherence, thresholds for intervention and disparities in treatment in people with type 2 diabetes in the UK |
title_full | Real-world evidence studies into treatment adherence, thresholds for intervention and disparities in treatment in people with type 2 diabetes in the UK |
title_fullStr | Real-world evidence studies into treatment adherence, thresholds for intervention and disparities in treatment in people with type 2 diabetes in the UK |
title_full_unstemmed | Real-world evidence studies into treatment adherence, thresholds for intervention and disparities in treatment in people with type 2 diabetes in the UK |
title_short | Real-world evidence studies into treatment adherence, thresholds for intervention and disparities in treatment in people with type 2 diabetes in the UK |
title_sort | real-world evidence studies into treatment adherence, thresholds for intervention and disparities in treatment in people with type 2 diabetes in the uk |
topic | Diabetes and Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5168506/ https://www.ncbi.nlm.nih.gov/pubmed/27884846 http://dx.doi.org/10.1136/bmjopen-2016-012801 |
work_keys_str_mv | AT mcgovernandrew realworldevidencestudiesintotreatmentadherencethresholdsforinterventionanddisparitiesintreatmentinpeoplewithtype2diabetesintheuk AT hintonwilliam realworldevidencestudiesintotreatmentadherencethresholdsforinterventionanddisparitiesintreatmentinpeoplewithtype2diabetesintheuk AT correaana realworldevidencestudiesintotreatmentadherencethresholdsforinterventionanddisparitiesintreatmentinpeoplewithtype2diabetesintheuk AT munroneil realworldevidencestudiesintotreatmentadherencethresholdsforinterventionanddisparitiesintreatmentinpeoplewithtype2diabetesintheuk AT whytemartin realworldevidencestudiesintotreatmentadherencethresholdsforinterventionanddisparitiesintreatmentinpeoplewithtype2diabetesintheuk AT delusignansimon realworldevidencestudiesintotreatmentadherencethresholdsforinterventionanddisparitiesintreatmentinpeoplewithtype2diabetesintheuk |